April 8, 2025: MDL Against Ozempic and Other GLP-1s Top 1,600 in April As of April 1, 2025, there are 1,685 active lawsuits pending against Novo Nordisk and other pharmaceutical companies that sold GLP-1 drugs like Ozempic
A moderate RAPD was noted in OD
Study findings revealed that once-weekly subcutaneous semaglutide showed the largest estimated effect on body weight and several metabolic markers, identifying the GLP-1 RA as a highly promising intervention for future clinical trials in psychiatric populations, although comparative rankings remain uncertain because the evidence base was small, heterogeneous, and largely indirect
These medicines include injectable formulations such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon BCise), as well as oral semaglutide (Rybelsus)